News
Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...
Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...
Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.
The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...
New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...
Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...
How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.
A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...
Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...
Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of ...
Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback